EXCLUSIVE-WHO DOCUMENT SAYS APPROVAL OF CHINESE VACCINES FROM SINOPHARM, SINOVAC POSSIBLE IN MARCH AT THE EARLIEST
Reuters 2021
| All information about SINOPHARM GROUP CO., LTD. |
|
|
|
|
|
|
|
| Gross sales 2020 |
459 B
71 088 M
51 817 M
|
| Internet earnings 2020 |
6 851 M
1 060 M
773 M
|
| Internet Debt 2020 |
15 485 M
2 397 M
1 747 M
|
| P/E ratio 2020 |
7,14x |
| Yield 2020 |
4,18% |
|
| Capitalization |
49 543 M
7 663 M
5 589 M
|
| EV / Gross sales 2020 |
0,14x |
| EV / Gross sales 2021 |
0,12x |
| Nbr of Staff |
93 764 |
| Free-Float |
43,0% |
|
| Chart SINOPHARM GROUP CO., LTD. |
|
Length :
Interval :
|
 |
|
|
Technical evaluation tendencies SINOPHARM GROUP CO., LTD.
|
Quick Time period |
Mid-Time period |
Lengthy Time period |
| Tendencies |
Bullish |
Impartial |
Impartial |
Revenue Assertion Evolution
| Imply consensus |
BUY |
| Variety of Analysts |
19 |
| Common goal price |
22,87 CNY |
| Final Shut price |
15,98 CNY |
| Unfold / Highest goal |
127% |
| Unfold / Common Target |
43,1% |
| Unfold / Lowest Target |
8,02% |
|
